Literature DB >> 25410088

Risk factors associated with Clostridium difficile infection in adult oncology patients.

Analia Rodríguez Garzotto1, Antonio Mérida García, Nerea Muñoz Unceta, M Mar Galera Lopez, M Ángeles Orellana-Miguel, C Vanesa Díaz-García, Susana Cortijo-Cascajares, Hernán Cortes-Funes, M Teresa Agulló-Ortuño.   

Abstract

PURPOSE: Clostridium difficile infection (CDI) prevention is particularly important for cancer patients, because diarrhea often results in dose reductions or delays of chemotherapy or radiotherapy. We conducted this study to better ascertain the incidence, susceptibility, and risk factors for CDI in cancer patients receiving chemotherapy at our hospital.
METHODS: We performed a retrospective study among adult cancer patients admitted at "12 de Octubre" University Hospital between January 2009 through April 2013 who were diagnosed with diarrhea. Inpatient data were available on hospital medical records. We screened by immunochromatography system detecting glutamate dehydrogenase antigen, and C. difficile toxins A and B. Later, a polymerase chain reaction for detecting toxin B gene was performed.
RESULTS: A total of 225 patients were included in the study, and 39 of them (17.3 %) were diagnosed with CDI. Type of tumor significantly differed between CDI patients, thus relative risk in each type of cancer was calculated after adjusting for age, antibiotic exposure, corticosteroid, and proton-pump inhibitor use. Patients with gastrointestinal tumors were less prone to CDI. Conversely, breast cancer patients have a greater predisposition to CDI. Antibiotic treatment was found to be associated with an increasing risk for CDI in breast cancer patients. Curiously, exposure to proton-pump inhibitors appeared protective in our cohort, except for lung cancer patients. However, we have not been able to find an association between a particular type of chemotherapy and CDI.
CONCLUSIONS: We underscore the urgent need for early recognition and diagnosis of CDI in cancer patients. Our findings indicate a probable association between antibiotic use and CDI incidence, at least in certain cancer, such as breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25410088     DOI: 10.1007/s00520-014-2506-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  31 in total

1.  Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia.

Authors:  Kenneth D Bishop; Jorge J Castillo
Journal:  Leuk Lymphoma       Date:  2012-01-31

2.  Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.

Authors:  Chun Shing Kwok; Aaron Kobina Arthur; Chukwudubem Ifeanyichukwu Anibueze; Sonal Singh; Rodrigo Cavallazzi; Yoon Kong Loke
Journal:  Am J Gastroenterol       Date:  2012-04-24       Impact factor: 10.864

Review 3.  A review of mortality due to Clostridium difficile infection.

Authors:  J A Karas; D A Enoch; S H Aliyu
Journal:  J Infect       Date:  2010-03-31       Impact factor: 6.072

4.  Clostridium difficile surveillance: a multicenter comparison of LabID events and use of standard definitions.

Authors:  Rosa Baier; Blake Morphis; Maureen Marsella; Leonard A Mermel
Journal:  Infect Control Hosp Epidemiol       Date:  2013-06       Impact factor: 3.254

5.  Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.

Authors:  Alexander Stein; Wieland Voigt; Karin Jordan
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

6.  Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.

Authors:  Alexa R Weingarden; Chi Chen; Aleh Bobr; Dan Yao; Yuwei Lu; Valerie M Nelson; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-27       Impact factor: 4.052

7.  Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.

Authors:  Oliver A Cornely; Mark A Miller; Bruno Fantin; Kathleen Mullane; Yin Kean; Sherwood Gorbach
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

Review 8.  Acid suppression and the risk of Clostridium difficile infection.

Authors:  Ethan A Mezoff; Mitchell B Cohen
Journal:  J Pediatr       Date:  2013-06-05       Impact factor: 4.406

9.  Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?

Authors:  Matthias G Hautmann; Matthias Hipp; Oliver Kölbl
Journal:  Radiat Oncol       Date:  2011-08-01       Impact factor: 3.481

10.  Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting.

Authors:  Jutta Zwielehner; Cornelia Lassl; Berit Hippe; Angelika Pointner; Olivier J Switzeny; Marlene Remely; Elvira Kitzweger; Reinhard Ruckser; Alexander G Haslberger
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

View more
  12 in total

1.  Risks factors and outcomes of Clostridium difficile infection in patients with cancer: a matched case-control study.

Authors:  Andrew I T Hebbard; Monica A Slavin; Caroline Reed; Jason A Trubiano; Benjamin W Teh; Gabrielle M Haeusler; Karin A Thursky; Leon J Worth
Journal:  Support Care Cancer       Date:  2017-02-02       Impact factor: 3.603

2.  Impact of malignancy on Clostridium difficile infection.

Authors:  M S Chung; J Kim; J O Kang; H Pai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-26       Impact factor: 3.267

3.  Intensity of Therapy for Malignancy and Risk for Recurrent and Complicated Clostridium difficile Infection in Children.

Authors:  Zachary I Willis; Maribeth R Nicholson; Adam J Esbenshade; Meng Xu; James C Slaughter; Debra L Friedman; Kathryn M Edwards; Maria C Di Pentima
Journal:  J Pediatr Hematol Oncol       Date:  2019-08       Impact factor: 1.289

Review 4.  Clostridium difficile Infection in Special High-Risk Populations.

Authors:  Alberto Cózar-Llistó; Antonio Ramos-Martinez; Javier Cobo
Journal:  Infect Dis Ther       Date:  2016-08-11

Review 5.  Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.

Authors:  Anca Trifan; Carol Stanciu; Irina Girleanu; Oana Cristina Stoica; Ana Maria Singeap; Roxana Maxim; Stefan Andrei Chiriac; Alin Ciobica; Lucian Boiculese
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

6.  Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation.

Authors:  Małgorzata Salamonowicz; T Ociepa; J Frączkiewicz; A Szmydki-Baran; M Matysiak; K Czyżewski; M Wysocki; P Gałązka; P Zalas-Więcek; N Irga-Jaworska; E Drożyńska; O Zając-Spychała; J Wachowiak; O Gryniewicz-Kwiatkowska; A Czajńska-Deptuła; B Dembowska-Bagińska; L Chełmecka-Wiktorczyk; W Balwierz; M Bartnik; K Zielezińska; T Urasiński; R Tomaszewska; T Szczepański; M Płonowski; M Krawczuk-Rybak; F Pierlejewski; W Młynarski; Z Gamrot-Pyka; M Woszczyk; Z Małas; W Badowska; A Urbanek-Dądela; G Karolczyk; W Stolpa; G Sobol-Milejska; A Zaucha-Prażmo; J Kowalczyk; J Goździk; E Gorczyńska; K Jermakow; A Król; A Chybicka; M Ussowicz; K Kałwak; J Styczyński
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-07-05       Impact factor: 3.267

Review 7.  2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients.

Authors:  Massimo Sartelli; Stefano Di Bella; Lynne V McFarland; Sahil Khanna; Luis Furuya-Kanamori; Nadir Abuzeid; Fikri M Abu-Zidan; Luca Ansaloni; Goran Augustin; Miklosh Bala; Offir Ben-Ishay; Walter L Biffl; Stephen M Brecher; Adrián Camacho-Ortiz; Miguel A Caínzos; Shirley Chan; Jill R Cherry-Bukowiec; Jesse Clanton; Federico Coccolini; Maria E Cocuz; Raul Coimbra; Francesco Cortese; Yunfeng Cui; Jacek Czepiel; Zaza Demetrashvili; Isidoro Di Carlo; Salomone Di Saverio; Irina M Dumitru; Christian Eckmann; Edward H Eiland; Joseph D Forrester; Gustavo P Fraga; Jean L Frossard; Donald E Fry; Rita Galeiras; Wagih Ghnnam; Carlos A Gomes; Ewen A Griffiths; Xavier Guirao; Mohamed H Ahmed; Torsten Herzog; Jae Il Kim; Tariq Iqbal; Arda Isik; Kamal M F Itani; Francesco M Labricciosa; Yeong Y Lee; Paul Juang; Aleksandar Karamarkovic; Peter K Kim; Yoram Kluger; Ari Leppaniemi; Varut Lohsiriwat; Gustavo M Machain; Sanjay Marwah; John E Mazuski; Gokhan Metan; Ernest E Moore; Frederick A Moore; Carlos A Ordoñez; Leonardo Pagani; Nicola Petrosillo; Francisco Portela; Kemal Rasa; Miran Rems; Boris E Sakakushev; Helmut Segovia-Lohse; Gabriele Sganga; Vishal G Shelat; Patrizia Spigaglia; Pierre Tattevin; Cristian Tranà; Libor Urbánek; Jan Ulrych; Pierluigi Viale; Gian L Baiocchi; Fausto Catena
Journal:  World J Emerg Surg       Date:  2019-02-28       Impact factor: 5.469

8.  Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients.

Authors:  Thorsten Fuereder; Danjel Koni; Andreas Gleiss; Michael Kundi; Athanasios Makristathis; Christoph Zielinski; Christoph Steininger
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

9.  Clostridium difficile Infections in Medical Intensive Care Units of a Medical Center in Southern Taiwan: Variable Seasonality and Disease Severity.

Authors:  Jen-Chieh Lee; Yuan-Pin Hung; Hsiao-Ju Lin; Pei-Jane Tsai; Wen-Chien Ko
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

10.  Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204.

Authors:  Yukihiro Toi; Takao Kobayashi; Toshiyuki Harada; Taku Nakagawa; Yoshiaki Mori; Tomoya Kuda; Shunichi Sugawara
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.